Eligi
Med
Ensayos clinicos
Suscripcion
Sobre EligiMed
Ensayos Clinicos | EligiMed
Ensayos clinicos
8.676 ensayos encontrados
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
INTERVENTIONAL
Inicio: 4 de may de 2012
ID: NCT01631214
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
INTERVENTIONAL
Inicio: 13 de dic de 2022
ID: NCT05624450
Reclutando
Fase 3
ClinicalTrials.gov
ONC201 for the Treatment of Newly Diagnosed H3 K27M-mutant Diffuse Glioma Following Completion of Radiotherapy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
INTERVENTIONAL
Inicio: 23 de ene de 2023
ID: NCT05580562
Completado
Fase 2
ClinicalTrials.gov
A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele
INTERVENTIONAL
Inicio: 15 de mar de 2023
ID: NCT05809934
Terminado
Fase 3
ClinicalTrials.gov
A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 52 Week, Phase III Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Non-Cystic Fibrosis Bronchiectasis (MAHALE)
INTERVENTIONAL
Inicio: 21 de jul de 2021
ID: NCT05006573
Activo, no recluta
Fase 2
ClinicalTrials.gov
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease
INTERVENTIONAL
Inicio: 28 de ago de 2024
ID: NCT06450197
Terminado
Fase 3
ClinicalTrials.gov
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
INTERVENTIONAL
Inicio: 25 de nov de 2019
ID: NCT04157335
Completado
Fase 3
ClinicalTrials.gov
A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix
INTERVENTIONAL
Inicio: 28 de jun de 2017
ID: NCT03185013
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.
INTERVENTIONAL
Inicio: 7 de ene de 2014
ID: NCT01994720
Completado
Fase 3
ClinicalTrials.gov
A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (DESTINATION)
INTERVENTIONAL
Inicio: 7 de ene de 2019
ID: NCT03706079
Completado
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.
INTERVENTIONAL
Inicio: 25 de jun de 2014
ID: NCT02155660
Reclutando
Fase 2
ClinicalTrials.gov
A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to High Dose Inhaled Corticosteroids
INTERVENTIONAL
Inicio: 26 de mar de 2025
ID: NCT06932263
Completado
ClinicalTrials.gov
Non-interventional Report on Parameters of Acceptability, Efficacy and Compliance of Fulvestrant in Post-menopausal Patients With Advanced Breast Cancer HR Positive Who Progresses to One Prior Endocrine Therapy With Antiestrogens
OBSERVATIONAL
Inicio: 1 de abr de 2009
ID: NCT00878930
Completado
Fase 3
ClinicalTrials.gov
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens
INTERVENTIONAL
Inicio: 1 de ene de 2013
ID: NCT01644643
Completado
Fase 3
ClinicalTrials.gov
A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Immediate-release Tolvaptan (OPC-41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease
INTERVENTIONAL
Inicio: 17 de oct de 2014
ID: NCT02251275
Terminado
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 16 de mar de 2018
ID: NCT03447769
Completado
Fase 3
ClinicalTrials.gov
A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma
INTERVENTIONAL
Inicio: 8 de dic de 2015
ID: NCT02571777
Completado
Fase 2
ClinicalTrials.gov
A 24-week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled, Phase 2 Study of Different Doses of VX-509 in Adult Subjects With Active Rheumatoid Arthritis on Stable Methotrexate Therapy With 104-Week Open Label Extension
INTERVENTIONAL
Inicio: 1 de abr de 2012
ID: NCT01590459
Completado
Fase 3
ClinicalTrials.gov
A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus
INTERVENTIONAL
Inicio: 9 de jul de 2015
ID: NCT02446899
Activo, no recluta
Fase 3
ClinicalTrials.gov
A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS
INTERVENTIONAL
Inicio: 31 de ago de 2021
ID: NCT05035212
Anterior
1
2
3
...
434
Siguiente
Filtros